Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (DE:MOL0)
FRANKFURT:MOL0
MOL0 Stock Chart & Stats
€6.45
--
Market closed
€6.45
--
Day’s Range― - ―
52-Week Range€6.45 - €6.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€11.91M
Enterprise Value-€690.59K
Total Cash (Recent Filing)€6.70M
Total Debt (Recent Filing)€390.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 20, 2026EPS Estimate
-5.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.43
Shares Outstanding3,079,229
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.54Price Target Upside218.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 2B/3 (MIRACLE) Program ProgressAdvancing a global pivotal trial and meeting enrollment milestones materially de-risks the regulatory pathway for Annamycin. A successful Phase 3 would enable a rolling NDA submission and commercialization pathway, making clinical progress a durable driver of long-term value and partnership interest.
Potential Non-cardiotoxic Profile For AnnamycinDemonstrated absence of cardiotoxicity in multiple trials could be a sustainable competitive advantage versus legacy anthracyclines, improving physician adoption and label differentiation. If confirmed in pivotal studies, this safety edge supports broad clinical uptake and a larger addressable market for Annamycin.
Capital Actions Restored Nasdaq Compliance And Improved EquityReclassifying warrants to equity and completing inducement financings materially improved the balance sheet and removed immediate delisting risk. These structural moves increase operational runway and preserve market listing, providing time to advance clinical programs and secure further partnerships or financing.
Bears Say
Sustained Negative Cash Generation And High BurnConsistent, large negative free cash flow indicates an ongoing dependence on external financing to fund trials and operations. This structural cash burn increases dilution risk, forces recurring capital raises or partnerships, and constrains strategic flexibility absent definitive clinical readouts or licensing deals.
Deteriorated Capital Position / Negative Stockholders' EquityA transition to negative equity reflects accumulated operating losses and a thin capital cushion, weakening the company's ability to absorb clinical setbacks. It elevates counterparty and investor concerns, may limit access to favorable financing, and increases the likelihood of dilutive transactions to fund development.
Pre-revenue Status With Large Recurring Operating LossesBeing a clinical-stage, pre-revenue firm means long lead times to commercialization and reliance on successful trials or partnerships. Large, recurring losses make sustainable margins contingent on drug approval and market uptake, amplifying binary outcome risk for investors and the company's long-term financial viability.
Moleculin Biotech News
MOL0 FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is €11.91M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2026 which is in 28 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 17, 2025. The company reported -€14.427 earnings per share for the quarter, missing the consensus estimate of -€5.582 by -€8.845.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -5.18.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 3,079,229 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -€14.427 in its last earnings report, missing expectations of -€5.582. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in DE:MOL0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
MOL0 Stock 12 Month Forecast
Average Price Target
€20.54
▲(218.50% Upside)